Furthermore, there were no statistically significant differences in OS between patients with ≥10% PD-L1-expressing tumor cells (TPS category 3 or higher) and patients with <10% PD-L1-expressing tumor cells (TPS category 2 or lower, p = 0.259), between people living with HIV and HIV-negative patients (p = 0.714), and between immunosuppressed and immunocompetent patients (p = 0.948). The gene discussed is CD274; the disease is neoplasm.